Investment case
Theravance Biopharma, Inc.
TBPH · 2 developments mapped · last assessed 2026-09-10
Market Ontology has mapped 2 macro, policy, and market developments to Theravance Biopharma, Inc. since 2026-08-21. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for TBPH yet, so no modelled value is shown. The TBPH valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run TBPH on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR
Direct acquisition of the company at a premium to its pre-announcement trading price.
· Moves implied acquisition premium, probability of deal close
- Main threat
Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger
Direct impact on merger completion probability and potential legal costs.
· Moves probability of merger completion, synergy realization timeline, legal expenses
What changed, by assumption
- 2026-08-21Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR
- 2026-09-10Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-10 | Revenue | Bullish | High confidence in achieving the $100 million 2026 milestone payment from Royalty Pharma based on TRELEGY global net sales. | 0.90 |
| 2026-06-29 | Valuation multiple | Bullish | Target re-rates to bid premium until close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-10 | Theravance Biopharma, Inc. provides update on litigation related to Zymeworks Inc. merger | Bearish | 1-3m | 0.70 |
| 2026-08-21 | Zymeworks Inc. to Acquire Theravance Biopharma, Inc. for $17.00 Per Share Plus CVR | Bullish | intraday | 0.90 |